دورية أكاديمية
أعرض في EDS

Tumor exposed-lymphatic endothelial cells promote primary tumor growth via IL6.

التفاصيل البيبلوغرافية
العنوان: Tumor exposed-lymphatic endothelial cells promote primary tumor growth via IL6.
المؤلفون: Van de Velde M; Laboratory of Tumor and Development Biology, GIGA-Cancer, Liege University, B23, Avenue Hippocrate 13, Sart-Tilman, B-4000, Liege, Belgium., Ebroin M; Laboratory of Tumor and Development Biology, GIGA-Cancer, Liege University, B23, Avenue Hippocrate 13, Sart-Tilman, B-4000, Liege, Belgium., Durré T; Laboratory of Tumor and Development Biology, GIGA-Cancer, Liege University, B23, Avenue Hippocrate 13, Sart-Tilman, B-4000, Liege, Belgium., Joiret M; Biomechanics Research Unit, GIGA-In Silico Medicine, Liege University, B34, Sart-Tilman, 4000, Liège, Belgium., Gillot L; Laboratory of Tumor and Development Biology, GIGA-Cancer, Liege University, B23, Avenue Hippocrate 13, Sart-Tilman, B-4000, Liege, Belgium., Blacher S; Laboratory of Tumor and Development Biology, GIGA-Cancer, Liege University, B23, Avenue Hippocrate 13, Sart-Tilman, B-4000, Liege, Belgium., Geris L; Biomechanics Research Unit, GIGA-In Silico Medicine, Liege University, B34, Sart-Tilman, 4000, Liège, Belgium., Kridelka F; Laboratory of Tumor and Development Biology, GIGA-Cancer, Liege University, B23, Avenue Hippocrate 13, Sart-Tilman, B-4000, Liege, Belgium; Department of Obstetrics and Gynecology, CHU Liege, Sart-Tilman, 4000, Liege, Belgium., Noel A; Laboratory of Tumor and Development Biology, GIGA-Cancer, Liege University, B23, Avenue Hippocrate 13, Sart-Tilman, B-4000, Liege, Belgium. Electronic address: agnes.noel@uliege.be.
المصدر: Cancer letters [Cancer Lett] 2021 Jan 28; Vol. 497, pp. 154-164. Date of Electronic Publication: 2020 Oct 17.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Ireland Country of Publication: Ireland NLM ID: 7600053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7980 (Electronic) Linking ISSN: 03043835 NLM ISO Abbreviation: Cancer Lett Subsets: MEDLINE
أسماء مطبوعة: Publication: Limerick : Elsevier Science Ireland
Original Publication: Amsterdam, Elsevier/North-Holland.
مواضيع طبية MeSH: Lymphangiogenesis*, Endothelial Cells/*pathology , Interleukin-6/*metabolism , Neovascularization, Pathologic/*pathology , Skin Neoplasms/*pathology, Animals ; Apoptosis ; Cell Movement ; Cell Proliferation ; Ear/physiopathology ; Endothelial Cells/metabolism ; Humans ; Interleukin-6/genetics ; Mice ; Mice, Nude ; Neoplasm Invasiveness ; Neovascularization, Pathologic/metabolism ; Skin Neoplasms/genetics ; Skin Neoplasms/metabolism ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
مستخلص: Solid tumors are composed of tumor cells and stromal cells including lymphatic endothelial cells (LEC), which are mainly viewed as cells forming lymphatic vessels involved in the transport of metastatic and immune cells. We here reveal a new mechanism by which tumor exposed-LEC (teLEC) exert mitogenic effects on tumor cells. Our conclusions are supported by morphological and molecular changes induced in teLEC that in turn enhance cancer cell invasion in 3D cultures and tumor cell proliferation in vivo. The characterization of teLEC secretome by RNA-Sequencing and cytokine array revealed that interleukine-6 (IL6) is one of the most modulated molecules in teLEC, whose production was negligible in unexposed LEC. Notably, neutralizing anti-human IL6 antibody abrogated teLEC-mediated mitogenic effects in vivo, when LEC were mixed with tumor cells in the ear sponge assay. We here assign a novel function to teLEC that is beyond their role of lymphatic vessel formation. This work highlights a new paradigm, in which teLEC exert "fibroblast-like properties", contribute in a paracrine manner to the control of tumor cell properties and are worth considering as key stromal determinant in future studies.
(Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.)
References: J Cell Biol. 1988 Mar;106(3):761-71. (PMID: 2450098)
Am J Pathol. 2001 Oct;159(4):1567-79. (PMID: 11583982)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Ann Surg Oncol. 2007 Feb;14(2):862-8. (PMID: 17103063)
Cardiovasc Res. 2016 Sep;111(4):310-21. (PMID: 27357637)
Oncoimmunology. 2018 May 31;7(8):e1462878. (PMID: 30221058)
Front Immunol. 2019 Jan 25;10:36. (PMID: 30740101)
BMC Cancer. 2015 Jul 04;15:498. (PMID: 26141595)
Neoplasia. 2005 Jan;7(1):57-66. (PMID: 15720817)
J Clin Invest. 2014 Mar;124(3):922-8. (PMID: 24590277)
Science. 2002 Jun 7;296(5574):1883-6. (PMID: 11976409)
Oncotarget. 2017 Jan 10;8(2):2863-2873. (PMID: 27926511)
J Clin Invest. 2011 May;121(5):2000-12. (PMID: 21540548)
Cancer Discov. 2019 Feb;9(2):282-301. (PMID: 30366930)
Prog Biophys Mol Biol. 2011 Aug;106(2):353-79. (PMID: 21736894)
Annu Rev Biomed Eng. 2016 Jul 11;18:125-58. (PMID: 26863922)
Angiogenesis. 2014 Apr;17(2):395-406. (PMID: 24141404)
Biomed Pharmacother. 2018 Dec;108:1415-1424. (PMID: 30372844)
Mol Aspects Med. 2011 Apr;32(2):146-58. (PMID: 21549745)
Biochem Soc Trans. 2018 Dec 17;46(6):1449-1462. (PMID: 30467123)
J Exp Med. 2017 Mar 6;214(3):579-596. (PMID: 28232471)
Circ Res. 2010 Mar 19;106(5):920-31. (PMID: 20133901)
Nat Rev Cancer. 2014 Mar;14(3):159-72. (PMID: 24561443)
J Clin Invest. 2016 Sep 1;126(9):3389-402. (PMID: 27525437)
J Clin Invest. 2014 Mar;124(3):878-87. (PMID: 24590272)
Curr Opin Immunol. 2018 Aug;53:7-12. (PMID: 29605736)
Int J Cancer. 2009 Dec 15;125(12):2747-56. (PMID: 19569051)
J Pathol. 2015 Aug;236(4):491-504. (PMID: 25880038)
Methods Mol Biol. 2018;1731:223-233. (PMID: 29318557)
Oncogene. 2007 May 10;26(21):2997-3005. (PMID: 17130836)
Curr Opin Immunol. 2018 Aug;53:64-73. (PMID: 29698919)
Cell. 2010 Feb 19;140(4):460-76. (PMID: 20178740)
Nat Rev Cancer. 2009 Apr;9(4):239-52. (PMID: 19279573)
J Cell Biol. 2018 Jun 4;217(6):2205-2221. (PMID: 29650776)
Sci Rep. 2017 Jan 27;7:41494. (PMID: 28128294)
Elife. 2018 May 01;7:. (PMID: 29712618)
Immunity. 2019 Sep 17;51(3):561-572.e5. (PMID: 31402260)
Br J Cancer. 2011 Jul 12;105(2):263-71. (PMID: 21629247)
Science. 2018 Mar 23;359(6382):1403-1407. (PMID: 29567713)
Int J Cancer. 2019 Nov 15;145(10):2804-2815. (PMID: 31344266)
J Exp Med. 2018 Jan 2;215(1):35-49. (PMID: 29242199)
Int J Cancer. 2011 Jun 15;128(12):2803-14. (PMID: 20726000)
Int J Cancer. 2014 Aug 1;135(3):551-62. (PMID: 23165423)
Oncogene. 2012 Oct 18;31(42):4499-508. (PMID: 22179834)
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):148-160. (PMID: 26705849)
J Clin Invest. 2014 Mar;124(3):943-52. (PMID: 24590280)
Science. 2018 Mar 23;359(6382):1408-1411. (PMID: 29567714)
Proc Natl Acad Sci U S A. 2013 May 28;110(22):9042-7. (PMID: 23671068)
J Exp Med. 2013 Jul 29;210(8):1509-28. (PMID: 23878309)
Differentiation. 2002 Dec;70(9-10):486-97. (PMID: 12492491)
فهرسة مساهمة: Keywords: CAF; Endothelial cell plasticity; Lymphangiogenesis; Lymphatic endothelial cells; Tumor microenvironment
المشرفين على المادة: 0 (Interleukin-6)
تواريخ الأحداث: Date Created: 20201020 Date Completed: 20210505 Latest Revision: 20210505
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC7723984
DOI: 10.1016/j.canlet.2020.10.020
PMID: 33080310
قاعدة البيانات: MEDLINE
الوصف
تدمد:1872-7980
DOI:10.1016/j.canlet.2020.10.020